title: Myocardial ischemia during intravenous prostacyclin administration: hemodynamic findings and precautionary measures.
abstract: This study reports coronary and systemic hemodynamics, and metabolic responses to atrial pacing, prostacyclin (PGI2), and iloprost, its stable analogue, in 16 patients with severe coronary obstruction as well as predominant narrowing in the left anterior descending artery. PGI2 caused ischemia in six patients with low anginal threshold during pacing. In three of them ischemia was also precipitated by iloprost. Drugs were infused at therapeutic doses and were discontinued when pain occurred. Angina disappeared promptly (less than or equal to 3 minutes) and spontaneously after the infusion of PGI2, whereas after the analogue it was long lasting (greater than or equal to 5 minutes) and was relieved by 125 mg intravenous aminophylline, an antagonist of dipyridamole-induced coronary dilation. Ischemia was associated with a drug-induced decrease in arterial blood pressure and reflex tachycardia, and occurred despite increased great cardiac vein (GCV) blood flow and decreased resistance, which is consistent with either a failure of regional flow to increase proportionally to the metabolic demand or a subendocardial-subepicardial steal. However, the following findings favor the latter hypothesis: heart rate and rate-pressure product at the onset of pain were lower with drugs than with pacing, and GCV blood flow, measured at a comparable heart rate, was less with pacing than with drugs. In conclusion, PGI2 and analogues may induce ischemia in patients with advanced coronary artery disease. The mechanism appears to be related to a dipyridamole-like maldistribution of flow. Counteraction of ischemia can be achieved by aminophylline.
mesh_terms: D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000009:adverse effects; D003327:Coronary Disease / Q000139:chemically induced* / Q000503:physiopathology; D011464:Epoprostenol / Q000008:administration & dosage / Q000009:adverse effects*; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D016285:Iloprost; D007275:Injections, Intravenous; D010138:Pacemaker, Artificial; D011453:Prostaglandins / Q000009:adverse effects
chemical_list: D002317:Cardiovascular Agents; D011453:Prostaglandins; D011464:Epoprostenol; D016285:Iloprost